Ibogaine for Peripheral Neuropathy and CIDP

People arrive at this question from a reasonable place. Ibogaine is described as neuroregenerative, neuropathy is nerve damage, and the two words appear to meet. They do not meet, and setting out exactly where they fail to meet is more useful than a flat refusal.

This page is about peripheral nerve. Ibogaine for Parkinson’s and MS covers the central nervous system claims, which is where nearly all of the argument actually lives.

Start with the absence

There is no literature to weigh. Everything below is about whether the mechanism could reach, not about what has been found in patients, because nothing has been found in patients.

What does exist, and why none of it is neuropathy

Four items sit close enough to be mistaken for evidence.

Only the last involves peripheral nerve, and it involves a nerve torn out of the spinal cord by injury. That is mechanical damage. CIDP is an immune system attacking myelin it has decided is foreign. Reasoning from one to the other is reasoning from a broken bone to arthritis because both involve the skeleton.

The 2026 review is worth reading on its own terms. It is honest about its status: it reviews literature and offers “a rationale for future investigation”. Its scope is white matter pathology in opioid use disorder, MS and traumatic brain injury. All three are central. Peripheral neuropathy is not in it.

Who wrote the patient reports

Both case reports come from Ambio Life Sciences, a company that sells ibogaine treatment. The MS paper’s own conflict of interest statement is unusually forthcoming, so it is quoted rather than characterised:

That does not make the observations false. It makes them the weakest evidence design in medicine, on an indication the authors sell, with no control, no blinding and no independent analysis. It is a reason to look harder, not a reason to conclude.

The mechanism, taken seriously

The argument deserves a proper hearing, because one part of it is genuinely sound.

GDNF really is a peripheral nerve growth factor. This is not a marketing invention. The medical index holds more than four hundred papers on GDNF and peripheral nerve regeneration, and about ninety on GDNF in Schwann cell myelination. Schwann cells are the cells that make peripheral myelin and the cells CIDP destroys. If a drug reliably raised GDNF in peripheral nerve, that would be a serious thing to investigate.

Ibogaine does raise GDNF. That is its best-established downstream effect and growth factors sets out what was measured.

So the syllogism looks tight. It has four holes.

1. The GDNF evidence is in the wrong tissue

Ibogaine’s GDNF work was done in the ventral tegmental area: midbrain dopamine neurons, the structure that matters for addiction. That is why the finding exists at all, and it is the proposed anti-addiction mechanism.

Nobody has measured GDNF in peripheral nerve, or in Schwann cells, after giving ibogaine. Not in a person, not in an animal. The step from midbrain dopamine neurons to a Schwann cell in a forearm is the entire argument, and it is unmeasured.

The same page notes the awkward detail that the rat study raised GDNF in the VTA but not in the substantia nigra. The effect was not even uniform across the brain.

2. It addresses the wrong half of the disease

This is the decisive one for CIDP.

CIDP is not primarily a failure of repair. It is an ongoing immune attack, in which T cells, macrophages, complement and in a substantial minority of patients specific autoantibodies against nodal proteins strip myelin from peripheral nerve. There are now well over a hundred papers on the antibody-defined subtypes alone.

A growth factor promotes repair. It does not stop an attack. Fertilising a field that is being grazed does not make the animals leave. Every established CIDP treatment, without exception, works by suppressing or removing the immune attack, and none of them works by promoting regrowth.

3. The one immune finding is at an unreachable concentration

There is a single study, from 1995, that tested ibogaine across immune assays. It found “dose-related suppression of all immune functions examined except macrophage function”, covering T-cell, B-cell and natural killer cell function. Taken alone, that sounds relevant.

It was measured at 10 to 100 micromolar.

Ibogaine blocks the hERG cardiac potassium channel at 3.53 micromolar, which is the concentration behind the cardiac risk that dominates every safety discussion of this drug. The immunosuppressive concentrations begin around three times higher and run to thirty times higher.

You would reach cardiotoxic concentrations well before immunomodulatory ones. That is not a therapeutic window. It is the absence of one.

The finding has also never been followed up. Searching the index for ibogaine and immunomodulation returns two records: this one, from 1995, and the 2026 review that cites it.

4. A chronic disease needs a chronic treatment

CIDP is managed over years. Immunoglobulin is typically re-infused every few weeks, indefinitely, because the attack resumes when treatment stops.

Ibogaine cannot be given that way. Its cardiac toxicity and its own neurological effects make repeated administration untenable, which is why every protocol in existence is built around one dose or a small number. A drug that can be given once is not a candidate for a disease that requires treatment every three weeks for a decade, whatever it does on the day.

This objection is independent of all the others. Even if the GDNF effect reached peripheral nerve, and even if the immune effect were achievable, the dosing pattern alone would rule it out.

The irony in the mechanism

The 2026 review argues that ibogaine’s NMDA, kappa opioid and sigma affinities produce “reduction in excitotoxicity” and thereby facilitate neuronal repair.

The classic account of ibogaine’s own neurotoxicity, published in 1997, is titled The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity.

The same mechanism appears on both sides of the ledger, as the therapeutic rationale in one paper and as the mode of neuronal destruction in another. Nobody has reconciled them. Brain regions covers the cerebellar damage, which is a real, reproducible, dose-dependent finding in animals.

And in the one modern trial to measure it carefully, every single participant developed clinical cerebellar ataxia. Whatever else is true, this is a drug that visibly disturbs neurological function in the short term, being proposed for people whose neurological function is already compromised.

What this means for someone with CIDP

CIDP is one of the few neuropathies with genuinely effective established treatment. Immunoglobulin, corticosteroids and plasma exchange all work, and a majority of patients respond to first-line therapy.

That is what makes this question different from most on this site. The risk is not mainly that ibogaine would fail. It is that untreated or under-treated CIDP causes axonal loss, and axons that die do not come back. Time spent on an unproven treatment is taken from a window in which a proven one still works, and the damage accrued in that window is permanent.

The useful question for a neurologist is not whether to add something from outside. It is whether the current regimen is optimised, and whether the antibody-defined subtypes have been excluded, since those respond poorly to immunoglobulin and better to other agents.

Where the idea would have to go instead

If the neurotrophic thread ever produces something for nerve repair, it will not be ibogaine, for the reasons above. It would be a compound built to keep the plasticity effects and drop the cardiac and hallucinogenic ones.

Those compounds exist. 18-MC barely blocks the hERG channel at all, and tabernanthalog was designed explicitly to separate the two. Both are covered on analogues, along with the fact that neither has a registered trial in any indication.

That is the honest shape of the answer. The theory points at something real, and it points away from iboga.

What we could not establish

Whether ibogaine raises GDNF anywhere outside the brain. No study has looked. This is the single measurement that would move the question, and it would be straightforward to do in an animal.

What the immunosuppression finding means in vivo. One in-vitro paper from 1995, never replicated, at concentrations that are cardiotoxic.

Whether the neuropathic pain case involved any nerve repair. Pain reduction after a nerve root avulsion has several explanations, including ibogaine’s known actions on pain signalling, that require no regeneration at all. The report does not distinguish between them.